The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands of percent.

Oklahoma's attorney general has accused CVS's Caremark pharmacy benefit manager unit of under-reimbursing pharmacies for prescription drugs.

Between 2017 and 2022, UnitedHealth Group’s Optum, Cigna’s Express Scripts and CVS Health’s CVS Caremark marked up their prices by hundreds — and in some cases, thousands — of percent, resulting in $7.3 billion in revenue above cost.

Attorney General Gentner Drummond sued CVS Caremark in an Oklahoma administrative court alleging that the company is under reimbursing pharmacies for prescription drugs.

Sen. James Lankford has been trying to pass legislation in response to an industry he believes will leave small towns without many pharmacy options.

But high medical costs contributed to results that disappointed Wall Street, and the company’s stock fell on the news that it had made less than analysts expected.

We recently published a list of 10 Companies Reflect Market Decline. In this article, we are going to take a look at where UnitedHealth Group Incorporated (NYSE:UNH) stands against other companies that reflect market decline.

CVS Health shares are trading lower by 2.7% during Thursday's session. Shares of insurers and pharmacy benefit manager stocks are trading lower in possible reaction to UnitedHealth's quarterly revenue miss.

Attorney General Gentner Drummond sued CVS Caremark Tuesday in an Oklahoma administrative court alleging that the company is under reimbursing pharmacies for prescription drugs. The lawsuit alleges CVS Caremark reimbursed Oklahoma pharmacies below the actual cost to acquire the drugs about 200 times between May and October 2024.

Cigna's Evernorth Health Services said on Wednesday its actions will enhance transparency about the company's negotiations.

CVS Health (CVS) on Tuesday announced the launch of the CVS Health app. The app, a successor to the CVS Pharmacy app and one of many

Healthcare stocks have been under the weather for the past few years, underperforming the broader market’s rally despite surges for obesity drugmakers Eli Lilly and Novo Nordisk. But the sector is off to a healthy start in 2025.